Patent Application: Cancer Treatment Compositions and Methods
Summary
The USPTO has published a new patent application (US20260085120A1) for compositions and methods related to cancer treatment. The application describes binding agents, carrier proteins, and therapeutic agents, particularly for cancers expressing PD-LI or PD-L2, and lyophilized compositions.
What changed
This document is a publication of a patent application filed with the USPTO, specifically application US20260085120A1, titled 'Carrier-PD-L1 Binding Agent Compositions for Treating Cancers.' The application details compositions involving binding agents and carrier proteins, optionally with therapeutic agents, and methods for their use in treating cancers. It also describes lyophilized compositions and methods for treating cancers by administering a nanoparticle composition and a PD-1 immunotherapy to patients whose cancer expresses PD-LI or PD-L2.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property and market exclusivity for novel cancer treatments. Companies in the pharmaceutical and biotechnology sectors should monitor the progress of this application and similar filings for insights into emerging therapeutic technologies and potential licensing or competitive landscapes.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Carrier-PD-L1 Binding Agent Compositions for Treating Cancers
Application US20260085120A1 Kind: A1 Mar 26, 2026
Inventors
Svetomir N. Markovic, Wendy K. Nevala
Abstract
Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-LI or PD-L2 by administering to the patient a nanoparticle composition and a PD-I immunotherapy.
CPC Classifications
C07K 16/2818 A61K 9/19 A61K 9/51 A61K 31/337 A61K 39/39558 A61K 45/06 A61P 35/00 C07K 16/2827 A61K 2039/505
Filing Date
2025-07-16
Application No.
19271543
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.